KT-621 BREADTH Phase 2b asthma data
Kymera expects to report results from its Phase 2b study of KT-621 (oral STAT6 degrader) for asthma in the second half of 2027 (no exact date yet). This is the first look at whether the drug did what the company hoped.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary
- Company
- Kymera Therapeutics, Inc. KYMR
- Drug
- KT-621 (oral STAT6 degrader)
- For
- asthma
- Stage
- Phase 2b
- When
- H2 2027 · the company gave a window, not a day; the calendar never invents one
- Source note
- BREADTH Phase 2b asthma trial ongoing; data expected to be reported in late 2027.
- Checked
- Checked by a person when it was added
- Source: biospace.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- KYMR headlines on this site
Kymera expects to report results from its Phase 2b (enrollment complete) study of KT-621 (oral STAT6 degrader) for moderate-to-severe atopic dermatitis in Q4 2026 (Oct–Dec) (no exact date yet). This is the first look at whether the drug did what the company hoped.
More details
- Entry
- KT-621 BROADEN2 Phase 2b topline data in atopic dermatitis · Clinical trial results (readout / topline data)
- Drug
- KT-621 (oral STAT6 degrader)
- For
- moderate-to-severe atopic dermatitis
- Stage
- Phase 2b (enrollment complete)
- When
- Q4 2026 · the company gave a window, not a day
- Source note
- Enrollment completed ~6 months early; topline data accelerated to "by year-end 2026" from prior mid-2027 guidance. ~200 patients, three doses vs placebo, 16 weeks.
- Checked
- Checked by a person when it was added
- Verify it
- Source: biospace.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- KYMR headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Kymera expects to report results from its Phase 1 study of KT-579 (oral IRF5 degrader) for immunology (lupus and other autoimmune diseases) in Q4 2026 (Oct–Dec) (no exact date yet). Phase 1 is an early safety study in a small group of people.
More details
- Entry
- KT-579 Phase 1 healthy volunteer data · Clinical trial results (readout / topline data)
- Drug
- KT-579 (oral IRF5 degrader)
- For
- immunology (lupus and other autoimmune diseases)
- Stage
- Phase 1 · an early safety study in a small group of people
- When
- Q4 2026 · the company gave a window, not a day
- Source note
- Phase 1 healthy volunteer trial ongoing with data expected in 4Q26; Phase 1b lupus proof-of-concept trial planned soon after.
- Checked
- Checked by a person when it was added
- Verify it
- Source: biospace.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- KYMR headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
KT-621 Phase 3 initiation in atopic dermatitis, expected in the first half of 2027 (no exact date yet). A company milestone for Kymera (KT-621 (oral STAT6 degrader) for moderate-to-severe atopic dermatitis): a step in the program rather than a decision or a data readout.
More details
- Entry
- KT-621 Phase 3 initiation in atopic dermatitis · Company milestone
- Drug
- KT-621 (oral STAT6 degrader)
- For
- moderate-to-severe atopic dermatitis
- Stage
- Phase 3 · the last stage before a drug can be approved
- When
- H1 2027 · the company gave a window, not a day
- Source note
- Subject to regulator discussions, company expects to initiate Phase 3 AD trials by mid-2027.
- Checked
- Checked by a person when it was added
- Verify it
- Source: biospace.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- KYMR headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Gilead IND filing for KT-200 CDK2 degrader, expected during 2027 (no exact date yet). A company milestone for Kymera (KT-200 for oncology (CDK2)): a step in the program rather than a decision or a data readout.
More details
- Entry
- Gilead IND filing for KT-200 CDK2 degrader · Company milestone
- Drug
- KT-200
- For
- oncology (CDK2)
- Stage
- Preclinical
- When
- 2027 · the company gave a window, not a day
- Source note
- Q2 2026 PR (Aug 5, 2026): Gilead exercised its exclusive license option on KT-200 in April 2026 ($45M milestone) and plans an IND filing in 2027. Same PR reiterates KT-621 BROADEN2 AD data by year-end 2026, Ph3 AD start by mid-2027, BREADTH asthma data late 2027, and KT-579 Ph1 HV data in 4Q26 (all already tracked).
- Checked
- Checked by a person when it was added
- Verify it
- Source: manilatimes.net ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- KYMR headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page